ArticleBMJ open2022

Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).

Sai Ping Lau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.